[Algorithm for selection of individual therapy with clopidogrel in vascular surgical practice].

For treatment of patients with diseases of lower limb arteries and prevention of cardiovascular complications in high-risk patients (those with diabetes mellitus, arterial hypertension, dyslipidemia, obesity) permanent antiplatelet therapy is indicated. A problem is variable individual sensitivity to therapeutic agents. For antiplatelet therapy in patients with atherosclerosis of lower limb arteries there has been obtained an evidence-supported base concerning efficacy of long-term administration of clopidogrel preparations, unlike patients with acute coronary syndrome, for whom there has been accumulated an evidence-confirmed base of administering clopidogrel preparations, as well as ticagrelor and prasugrel in various clinical situations.

[Comparison of Empiric and Pharmacogenetic Approaches in Assessment of Efficacy of Anticoagulant Therapy].

We compared pharmacogenetic (PG) and standard approaches to selection of individual dose of warfarin on 2 groups of patients each comprising 17 persons. In the group with PG selection we took into consideration the result of preliminary genotyping of polymorphisms of VKORC1 and CYP2C9 genes known to be associated with individual warfarin dose. Control of warfarin therapy was carried out during 6 months, number of measurements of international normalized ratio (INR) exceeded 500.

[Comparison of Empiric and Pharmacogenetic Approaches in Assessment of Efficacy of Anticoagulant Therapy].

We compared pharmacogenetic (PG) and standard approaches to selection of individual dose of warfarin on 2 groups of patients each comprising 17 persons. In the group with PG selection we took into consideration the result of preliminary genotyping of polymorphisms of VKORC1 and CYP2C9 genes known to be associated with individual warfarin dose. Control of warfarin therapy was carried out during 6 months, number of measurements of international normalized ratio (INR) exceeded 500.